VivoSeq
Neurology

Myasthenia Gravis, Generalized

2

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Myasthenia Gravis, Generalized is an early-stage landscape with 2 programs across 3 companies. The most active players are Vertex Pharmaceuticals, Dianthus Therapeutics, Eli Lilly. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

1 program

Phase 2D

Dianthus Therapeutics

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Povetacicept

Vertex Pharmaceuticals

Phase 31

Claseprubart

Dianthus Therapeutics

Approved
No programs

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients With Generalized Myasthenia Gravis (EMERGE)
Recruiting·DDianthus Therapeutics·Phase 3·NCT07647510·195 enrolled
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults With Generalized Myasthenia Gravis
Recruiting·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Phase 2·NCT07501702·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)